ADMA Biologics, Inc. Secures Up to $6 Million Term Loan Commitment to Advance Phase III Study

Published: Jan 07, 2013

HACKENSACK, N.J.--(BUSINESS WIRE)--ADMA Biologics, Inc.(ADMA), a late-stage biotechnology company focused on developing specialty immune globulin therapeutics and the commercialization of human plasma, announced it has entered into a $6 million term loan commitment with Hercules Technology Growth Capital, Inc., (Hercules: NYSE: HTGC).

Back to news